{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T11:20:42Z","timestamp":1783336842094,"version":"3.54.6"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T00:00:00Z","timestamp":1724457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T00:00:00Z","timestamp":1724457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-024-05695-1","type":"journal-article","created":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T10:04:59Z","timestamp":1724493899000},"page":"1959-1966","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Tocilizumab plus Nintedanib for progressive interstitial lung disease in systemic sclerosis: a one-year observational study"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3720-5996","authenticated-orcid":false,"given":"Stylianos","family":"Panopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7030-6166","authenticated-orcid":false,"given":"Vasilios","family":"Tzilas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2162-1362","authenticated-orcid":false,"given":"Vasiliki-Kalliopi","family":"Bournia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2238-0975","authenticated-orcid":false,"given":"Maria G.","family":"Tektonidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5484-2930","authenticated-orcid":false,"given":"Petros P.","family":"Sfikakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,24]]},"reference":[{"key":"5695_CR1","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","volume":"390","author":"CP Denton","year":"2017","unstructured":"Denton CP, Khanna D (2017) Systemic sclerosis. Lancet (London England) 390:1685\u20131699","journal-title":"Lancet (London England)"},{"key":"5695_CR2","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/S0140-6736(22)01692-0","volume":"401","author":"ER Volkmann","year":"2023","unstructured":"Volkmann ER, Andr\u00e9asson K, Smith V (2023) Systemic sclerosis. Lancet 401:304\u2013318","journal-title":"Lancet"},{"key":"5695_CR3","doi-asserted-by":"publisher","first-page":"e001694","DOI":"10.1136\/rmdopen-2021-001694","volume":"7","author":"VK Bournia","year":"2021","unstructured":"Bournia VK, Fragoulis GE, Mitrou P, Mathioudakis K, Tsolakidis A, Konstantonis G et al (2021) All-cause mortality in systemic rheumatic diseases under treatment compared with the general population, 2015\u20132019. RMD open 7:e001694","journal-title":"RMD open"},{"key":"5695_CR4","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.autrev.2018.02.008","volume":"17","author":"S Panopoulos","year":"2018","unstructured":"Panopoulos S, Bournia VK, Konstantonis G, Fragiadaki K, Sfikakis PP, Tektonidou MG (2018) Predictors of morbidity and mortality in early systemic sclerosis: long-term follow-up data from a single-centre inception cohort. Autoimmun rev 17:816\u2013820","journal-title":"Autoimmun rev"},{"key":"5695_CR5","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1136\/annrheumdis-2020-217455","volume":"80","author":"AM Hoffmann-Vold","year":"2021","unstructured":"Hoffmann-Vold AM, Allanore Y, Alves M, Brunborg C, Air\u00f3 P, Ananieva LP et al (2021) Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Ann Rheum Dis 80:219\u2013227","journal-title":"Ann Rheum Dis"},{"key":"5695_CR6","doi-asserted-by":"publisher","unstructured":"Morrisroe K, Hansen D, Stevens W, Ross L, Sahhar J, Ngian GS et al Progressive pulmonary fibrosis and its impact on survival in systemic sclerosis related interstitial lung disease. Rheumatology (Oxford).2023:kead491.https:\/\/doi.org\/10.1093\/rheumatology\/kead491","DOI":"10.1093\/rheumatology\/kead491"},{"key":"5695_CR7","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1136\/ard.2009.114264","volume":"69","author":"AJ Tyndall","year":"2010","unstructured":"Tyndall AJ, Bannert B, Vonk M, Airo P, Cozzi F, Carreira PE et al (2010) Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma trials and Research (EUSTAR) database. Ann Rheum Dis 69:1809\u20131815","journal-title":"Ann Rheum Dis"},{"key":"5695_CR8","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y et al (2017) Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 76:1327\u20131339","journal-title":"Ann Rheum Dis"},{"key":"5695_CR9","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC et al (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4:708\u2013719","journal-title":"Lancet Respir Med"},{"key":"5695_CR10","doi-asserted-by":"publisher","first-page":"e0177107","DOI":"10.1371\/journal.pone.0177107","volume":"12","author":"M Baqir","year":"2017","unstructured":"Baqir M, Makol A, Osborn TG, Bartholmai BJ, Ryu JH (2017) Mycophenolate mofetil for sclerodermarelated interstitial lung disease: a real world experience. PLoS ONE 12:e0177107","journal-title":"PLoS ONE"},{"key":"5695_CR11","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41584-023-00909-5","volume":"19","author":"JE Pope","year":"2023","unstructured":"Pope JE, Denton CP, Johnson SR, Fernandez-Codina A, Hudson M, Nevskaya T (2023) State-of-the-art evidence in the treatment of systemic sclerosis. Nat Rev Rheumatol 19:212\u2013226","journal-title":"Nat Rev Rheumatol"},{"key":"5695_CR12","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/rheumatology\/keaa550","volume":"60","author":"RP Goswami","year":"2021","unstructured":"Goswami RP, Ray A, Chatterjee M, Mukherjee A, Sircar G, Ghosh P (2021) Rituximab in the treatment of systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis. Rheumatology (Oxford) 60:557\u2013567","journal-title":"Rheumatology (Oxford)"},{"key":"5695_CR13","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.semarthrit.2016.10.003","volume":"46","author":"D Daoussis","year":"2017","unstructured":"Daoussis D, Melissaropoulos K, Sakellaropoulos G, Antonopoulos I, Markatseli TE, Simopoulou T et al (2017) A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease. Semin Arthritis Rheum 46:625\u2013631","journal-title":"Semin Arthritis Rheum"},{"key":"5695_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","volume":"11","author":"TM Maher","year":"2023","unstructured":"Maher TM, Tudor VA, Saunders P, Gibbons MA, Fletcher SV, Denton CP et al (2023) Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial. Lancet Respir Med 11:45\u201354","journal-title":"Lancet Respir Med"},{"key":"5695_CR15","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1703327","volume":"378","author":"KM Sullivan","year":"2018","unstructured":"Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B et al (2018) Myeloablative autologous stem-cell transplantation for severe Scleroderma. N Engl J Med 378:35\u201347","journal-title":"N Engl J Med"},{"key":"5695_CR16","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1001\/jama.2014.6368","volume":"311","author":"JM van Laar","year":"2014","unstructured":"van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J et al (2014) Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 311:2490\u20132498","journal-title":"JAMA"},{"key":"5695_CR17","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.healun.2018.03.003","volume":"37","author":"P Prad\u00e8re","year":"2018","unstructured":"Prad\u00e8re P, Tudorache I, Magnusson J, Savale L, Brugiere O, Douvry B et al (2018) Lung transplantation for scleroderma lung disease: an international, multicenter, observational cohort study. J Heart Lung Transpl 37:903\u2013911","journal-title":"J Heart Lung Transpl"},{"key":"5695_CR18","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1136\/annrheumdis-2018-213031","volume":"77","author":"CP Denton","year":"2018","unstructured":"Denton CP, Ong VH, Xu S, Chen-Harris H, Modrusan Z, Lafyatis R et al (2018) Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis. Ann Rheum Dis 77:1362\u20131371","journal-title":"Ann Rheum Dis"},{"key":"5695_CR19","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","volume":"387","author":"D Khanna","year":"2016","unstructured":"Khanna D, Denton CP, Jahreis A, van Laar JM, Frech TM, Anderson ME et al (2016) Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet (London England) 387:2630\u20132640","journal-title":"Lancet (London England)"},{"key":"5695_CR20","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","volume":"8","author":"D Khanna","year":"2020","unstructured":"Khanna D, Lin CJF, Furst DE, Goldin J, Kim G, Kuwana M et al (2020) Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 8:963\u2013974","journal-title":"Lancet Respir Med"},{"key":"5695_CR21","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1002\/art.41668","volume":"73","author":"D Roofeh","year":"2021","unstructured":"Roofeh D, Lin CJF, Goldin J, Kim GH, Furst DE, Denton CP et al (2021) Tocilizumab prevents progression of early systemic sclerosis Associated interstitial lung disease. Arthritis Rheumatol 73:1301\u20131310","journal-title":"Arthritis Rheumatol"},{"key":"5695_CR22","doi-asserted-by":"publisher","first-page":"e002477","DOI":"10.1136\/rmdopen-2022-002477","volume":"8","author":"S Kuster","year":"2022","unstructured":"Kuster S, Jordan S, Elhai M, Held U, Steigmiller K, Bruni C et al (2022) Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort. RMD open 8:e002477","journal-title":"RMD open"},{"key":"5695_CR23","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3899\/jrheum.210273","volume":"49","author":"ST Panopoulos","year":"2022","unstructured":"Panopoulos ST, Tektonidou MG, Bournia VK, Arida A, Sfikakis PP (2022) Anti-interleukin 6 Therapy Effect for Refractory Joint and skin involvement in systemic sclerosis: a Real-world, single-center experience. J Rheumatol 49:68\u201373","journal-title":"J Rheumatol"},{"key":"5695_CR24","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1136\/annrheumdis-2018-214449","volume":"78","author":"J Narv\u00e1ez","year":"2019","unstructured":"Narv\u00e1ez J, Lluch J, Alegre Sancho JJ, Molina-Molina M, Nolla JM, Castellv\u00ed I (2019) Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: a case series. Ann Rheum Dis 78:e123","journal-title":"Ann Rheum Dis"},{"key":"5695_CR25","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1513\/AnnalsATS.202301-056OC","volume":"21","author":"M Ghazipura","year":"2024","unstructured":"Ghazipura M, Macrea M, Herman D, Barnes H, Knight SL, Silver RM et al (2024) Tocilizumab in patients with systemic sclerosis-associated interstitial lung disease: a systematic review and Meta-analysis. Ann Am Thorac Soc 21:328\u2013337","journal-title":"Ann Am Thorac Soc"},{"key":"5695_CR26","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD et al (2019) Nintedanib for systemic sclerosis\u2013Associated interstitial lung disease. N Engl J Med 380:2518\u20132528","journal-title":"N Engl J Med"},{"key":"5695_CR27","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/art.38098","volume":"65","author":"F Van Den Hoogen","year":"2013","unstructured":"Van Den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A et al (2013) 2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative. Arthritis Rheum 65:2737\u20132747","journal-title":"Arthritis Rheum"},{"key":"5695_CR28","doi-asserted-by":"publisher","first-page":"2102571","DOI":"10.1183\/13993003.02571-2021","volume":"60","author":"N Hambly","year":"2022","unstructured":"Hambly N, Farooqi MM, Dvorkin-Gheva A, Donohoe K, Garlick K, Scallan C et al (2022) Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry. Eur Respir J 60:2102571","journal-title":"Eur Respir J"},{"key":"5695_CR29","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1136\/annrheumdis-2016-209768","volume":"76","author":"G Valentini","year":"2017","unstructured":"Valentini G, Iudici M, Walker UA, Jaeger VK, Baron M, Carreira P et al (2017) The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. Ann Rheum Dis 76:270\u2013276","journal-title":"Ann Rheum Dis"},{"key":"5695_CR30","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1136\/ard.2005.050187","volume":"65","author":"D Khanna","year":"2006","unstructured":"Khanna D, Furst DE, Hays RD, Park GS, Wong WK, Seibold JR et al (2006) Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study. Ann Rheum Dis 65:1325\u20131329","journal-title":"Ann Rheum Dis"},{"key":"5695_CR31","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1378\/chest.09-0108","volume":"136","author":"J Goldin","year":"2009","unstructured":"Goldin J, Elashoff R, Kim HJ, Yan X, Lynch D, Strollo D et al (2009) Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study. Chest 136:1333\u20131340","journal-title":"Chest"},{"key":"5695_CR32","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","volume":"177","author":"NSL Goh","year":"2008","unstructured":"Goh NSL, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM et al (2008) Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 177:1248\u20131254","journal-title":"Am J Respir Crit Care Med"},{"key":"5695_CR33","doi-asserted-by":"publisher","first-page":"e002850","DOI":"10.1136\/rmdopen-2022-002850","volume":"9","author":"C Campochiaro","year":"2023","unstructured":"Campochiaro C, De Luca G, Lazzaroni MG, Armentaro G, Spinella A, Vigone B et al (2023) Original research: real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study. RMD Open 9:e002850","journal-title":"RMD Open"},{"key":"5695_CR34","first-page":"1045","volume":"74","author":"D Khanna","year":"2022","unstructured":"Khanna D, Spino C, Bernstein E, Goldin J, Tashkin D, Roth M (2022) Combination therapy of Mycophenolate Mofetil and Pirfenidone vs. mycophenolate alone: results from the Scleroderma Lung Study III. Arthritis Rheumatol 74:1045\u20131047","journal-title":"Arthritis Rheumatol"},{"key":"5695_CR35","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.3390\/diagnostics13071221","volume":"13","author":"M Boutel","year":"2023","unstructured":"Boutel M, Boutou A, Pitsiou G, Garyfallos A, Dimitroulas T (2023) Efficacy and safety of Nintedanib in patients with connective tissue disease-interstitial lung disease (CTD-ILD): a real-world single Center experience. Diagnostics (Basel) 13:1221","journal-title":"Diagnostics (Basel)"},{"key":"5695_CR36","first-page":"A247","volume":"78","author":"M Naqvi","year":"2023","unstructured":"Naqvi M, Lawrence A, Myall K (2023) Nintedanib in combination with immunosuppressant drug prescribing is safe and well tolerated in a large cohort of patients with progressive fibrotic interstitial lung disease. Thorax 78:A247","journal-title":"Thorax"},{"key":"5695_CR37","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1164\/rccm.201908-1640OC","volume":"201","author":"RJ White","year":"2020","unstructured":"White RJ, Jerjes-Sanchez C, Meyer GMB, Pulido T, Sepulveda P, Wang KY et al (2020) Combination therapy with oral Treprostinil for Pulmonary arterial hypertension. A double-blind placebo-controlled clinical trial. Am J Respir Crit Care Med 201:707\u2013717","journal-title":"Am J Respir Crit Care Med"},{"key":"5695_CR38","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1136\/annrheumdis-2016-210236","volume":"76","author":"JG Coghlan","year":"2017","unstructured":"Coghlan JG, Gali\u00e8 N, Barber\u00e0 JA, Frost AE, Ghofrani HA, Hoeper MM et al (2017) Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Ann Rheum Dis 76:1219\u20131227","journal-title":"Ann Rheum Dis"},{"key":"5695_CR39","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1183\/16000617.0085-2016","volume":"25","author":"O Sitbon","year":"2016","unstructured":"Sitbon O, Gaine S (2016) Beyond a single pathway: combination therapy in pulmonary arterial hypertension. Eur Respir Rev 25:408","journal-title":"Eur Respir Rev"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-024-05695-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-024-05695-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-024-05695-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T02:07:22Z","timestamp":1726193242000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-024-05695-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,24]]},"references-count":39,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["5695"],"URL":"https:\/\/doi.org\/10.1007\/s00296-024-05695-1","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,24]]},"assertion":[{"value":"19 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the ethics committee of Laikon University Hospital (approval number 686\/23-06-2011) and all patients gave written informed for their personal data analysis","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"S. Panopoulos has received consultant fees and honoraria for lectures from Pfizer, Aenorasis, Amgen, Farmaserv Lilly, and Abbvie; V. Tzilas declares no conflict of interest; V-K Bournia declares no conflict of interest; M. Tektonidou has received consulting fees from El Lilly, GSK, and UCB and unrestricted grants from GSK, Faran, DEMO, Vianex and UCB; P. Sfikakis has received consultant fees from Actelion, Pfizer, Genesis, MSD, UCB, Boehringer Ingelheim, Aenorasis, Farmaserv Lilly, Gilead, Abbvie, and Novartis, and grant\/research support from Abbvie, Roche, Pfzer, Faran, Amgen, Jannsen, Boehringer Ingelheim, and Gilead.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}